glp-1 agonist consultation process receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Perioperative Use of GLP-1 Receptor
Description
doi: 10.1073/pnas.2014879117 [DOI] [PMC free article] [PubMed] [Google Scholar] 98.Frias JP, Hsia S, Eyde S, et al
Regarding BMI, our results showed that GLP-1 agonists had a progressive impact on BMI reduction over time, with statistically significant effects emerging at 6 months and persisting up to 24 months, at 3 months, the mean difference (MD) was 0.36 (95% CI: 1.22, 0.50) with 0.0% heterogeneity ( I 2 ) and a p -value of 0.4102
Weight-loss surgery effectively reduces weight and complications in patients with severe obesity
Tirzepatide was approved in 2022
